Low Serum Paraoxonase-1 Lactonase and Arylesterase Activities in Obese Children and Adolescents

Open access

Abstract

Serum paraoxonase-1 (PON1) binds mainly to high density lipoproteins (HDLs) and protects low density lipoproteins (LDLs) against oxidation. While paraoxonase and arylesterase activities are traditionally assayed, lactonase activity, accounting for protection against LDL oxidation, was less investigated in obese children and adolescents. Therefore, we aimed to measure lactonase, paraoxonase and arylesterase activities, oxidized LDL (ox-LDL) and malondialdehyde (MDA) levels in obese children and adolescents.

Study population included 68 children (35 obese and 33 normal-weight). Arylesterase and paraoxonase activities were assayed spectrophotometrically. Lactonase activity, ox-LDL and MDA levels were measured using a pH-sensitive colorimetric assay, an ELISA technique and a fluorimetric method, respectively. The lipid profile was assessed by common methods.

Lactonase and arylesterase activities were decreased in the presence of obesity. MDA, but not ox-LDL levels, showed significant differences between groups. Multiple regression analysis identified a reciprocal relationship and a possible association between lactonase and arylesterase activities and obesity.

1. Sorenson RC, Bisgaier CL, Aviram M, Hsu C, Billecke S, La Du BN. Human serum paraoxonase/arylesterase’s retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: Apolipoprotein A-I stabilizes activity. Arterioscler Thromb Vasc Bio. 1999;19:2214-25. DOI: 10.1161/01. ATV.19.9.2214

2. Khersonsky O, Tawfik D. Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry. 2005;44(16):6371-82. DOI: 10.1021/bi047440d

3. Ben-David M, Elias M, Filippi JJ, Du-ach E, Silman I, Sussman JL, et al. Catalytic versatility and backups in enzyme active sites: the case of serum paraoxonase 1. J Mol Biol. 2012 May;418(3-4):181–96. DOI: 10.1016/j.jmb.2012.02.042

4. Aviram M, Kaplan M, Rosenblat M, Fuhrman B. Dietary antioxidants and paraoxonases against LDL oxidation and atherosclerosis development. Handb Exp Pharma. 2005;170:263–300. DOI: 10.1007/3-540-27661-0_9

5. Deakin SP, James RW. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clin Sci (Lond). 2004 Nov;107(5):435–47. DOI: 10.1042/CS20040187

6. Browne RW, Koury ST, Marion S, Wilding G, Muti P, Trevisan M. Accuracy and biological variation of human serum Paraoxonase-1 activity and polymorphism (Q192R) by kinetic enzyme assay. Clin Chem. 2007 Feb;53(2):310–7. DOI: 10.1373/clinchem.2006.074559

7. Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet. 1983 Nov;35(6):1126-38.

8. Nguyen SD, Nguyen DH, Park CH, Kim MR, Sok DE. Oxidative inactivation of lactonase activity of purified human Paraoxonase-1(PON1). Biochim Biophys Acta. 2009 Mar;1790(3):155-60. DOI: 10.1016/j. bbagen.2008.11.009

9. Fuhrman B. Regulation of hepatic paraoxonase-1 expression. J Lipids. 2012; 2012:684010. DOI: 10.1155/2012/684010

10. She ZG, Chen HZ, Yan Y, Li H, Liu DP. The human paraoxonase gene cluster as a target in the treatment of atherosclerosis. Antioxid Redox Signal. 2012 Mar;16(6):597-632. DOI: 10.1089/ars.2010.3774

11. Koncsos P, Seres I, Harangi M, Illyés I, Józsa L, Gönczi F, et al. Human paraoxonase-1 activity in childhood obesity and its relation to leptin and adiponectin levels. Pediatr Res. 2010 Mar;67(3):309-13. DOI: 10.1203/PDR.0b013e3181c9fb66

12. Seres I, Bajnok L, Harangi M, Sztanek F, Koncsos P, Paragh G. Alteration of PON1 activity in adult and childhood obesity and its relation to adipokine levels. Adv Exp Med Biol. 2010;660:129-42. DOI: 10.1007/978-1-60761-350-3_12

13. Torun E, Gökçe S, Ozgen İT, Aydın S, Cesur Y. Serum paraoxonase activity and oxidative stress and their relationship with obesity-related metabolic syndrome and non-alcoholic fatty liver disease in obese children and adolescents. J Pediatr Endocrinol Metab. 2014 Jul;27(7-8):667-75. DOI: 10.1515/jpem-2013-0337

14. Ferré N, Feliu A, García-Heredia A, Marsillach J, París N, Zaragoza-Jordana M, et al. Impaired paraoxonase-1 status in obese children. Relationships with insulin resistance and metabolic syndrome. Clin Biochem. 2013 Dec;46(18):1830-6. DOI: 10.1016/j.clinbiochem.2013.08.020

15. Conti M, Moran PC, Levillain P, Lemonnier A. Improved fluorimetric determination of malondialdehyde. Clin Chem. 1991 Jul;37(7):1273-5.

16. Dobiásová M. AIP-atherogenic index of plasma as a significant predictor of cardiovascular risk: from research to practice. Vnitr Lek. 2006 Jan;52(1):64-71.

17. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: the R Foundation for Statistical Computing. 2011; ISBN: 3-900051-07-0. Available online at http://www.R-project.org/.

18. Aslan M, Horoz M, Sabuncu T, Celik H, Selek S. Serum paraoxonase enzyme activity and oxidative stress in obese subjects. Pol Arch Med Wewn. 2011 Jun;121(6):181–6.

19. Ferretti G, Bacchetti T, Moroni C, Savino S, Liuzzi A, Balzola F, et al. Paraoxonase activity in high-density lipoproteins: a comparison between healthy and obese females. J Clin Endocrinol Metab. 2005 Mar;90(3):1728–33. DOI: 10.1210/jc.2004-0486

20. Liang KW, Lee WJ, Lee IT, Lee WL, Lin SY, Hsu SL, et al. Persistent elevation of paraoxonase-1 specific enzyme activity after weight reduction in obese non-diabetic men with metabolic syndrome. Clin Chim Acta. 2011 Sep 18;412(19-20):1835-41. DOI: 10.1016/j. cca.2011.06.018

21. Samy W, Hassanian MA. Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin. Arab J Gastroenterol. 2011 Jun;12(2):80-5. DOI: 10.1016/j.ajg.2011.04.008

22. Tabur S, Torun AN, Sabuncu T, Turan MN, Celik H, Ocak AR, et al. Non-diabetic metabolic syndrome and obesity do not affect serum paraoxonase and arylesterase activities but do affect oxidative stress and inflammation. Eur J Endocrinol. 2010 Mar;162(3):535–41. DOI: 10.1530/EJE-09-0732

23. Krzystek-Korpacka M, Patryn E, Hotowy K, Czapińska E, Majda J, Kustrzeba-Wójcicka I, et al. Paraoxonase (PON)-1 activity in overweight and obese children and adolescents: association with obesity-related inflammation and oxidative stress. Adv Clin Exp Med. 2013 Mar-Apr;22(2):229-36.

24. Zaki ME, El-Bassyouni H, Kamal S, El-Gammal M, Youness E. Association of serum paraoxonase enzyme activity and oxidative stress markers with dyslipidemia in obese adolescents. Indian J Endocrinol and Metab. 2014 May-Jun;18(3):340-4. DOI: 10.4103/2230-8210.131173

25. Rupérez AI, López-Guarnido O, Gil F, Olza J, Gil-Campos M, Leis R, et al. Paraoxonase-1 activities and genetic variation in childhood obesity. Br J Nutr. 2013 Nov;110(9):1639-47. DOI: 10.1017/S0007114513001967

26. Agirbasli M, Tanrikulu A, Erkus E, Azizy M, Sevim BA, Kaya Z, et al. Serum paraoxonase-1 activity in children: the effects of obesity and insulin resistance. Acta Cardiol. 2014 Dec;69(6):679-85.

27. Desai S, Baker SS, Liu W, Moya DA, Browne RW, Mastrandrea L, et al. Paraoxonase 1 and oxidative stress in paediatric non-alcoholic steatohepatitis. Liver Int. 2014 Jan;34(1):110-7. DOI: 10.1111/liv.12308

28. Huen K, Harley K, Beckman K, Eskenazi B, Holland N. Associations of PON1 and Genetic Ancestry with Obesity in Early Childhood. PLoS ONE. 2013 May;8(5):e62565. DOI: 10.1371/journal.pone.0062565

29. Chapman E, Wong CH. A pH sensitive colorimetric assay for the high-throughput screening of enzyme inhibitors and substrates: a case study using kinases. Bioorg Med Chem. 2002 Mar;10(3):551-5. DOI: 10.1016/S0968-0896(01)00306-6

30. James RW, Deakin SP. The importance of high-density lipoproteins for paraoxonase-1 secretion, stability, and activity. Free Radic Biol Med. 2004 Dec;37(12):1986-94. DOI: 10.1016/j.freeradbiomed.2004.08.012

31. Gaidukov L, Tawfik DS. High affinity, stability and lactonase activity of serum paraoxonase PON1 anchored on HDL with ApoA-I. Biochemistry. 2005 Sep;44(35):11843-54. DOI: 10.1021/bi050862i

32. Noto H, Hashimoto Y, Satoh H, Hara M, Iso-o N, Togo M, et al. Exclusive association of Paraoxonase-1with high-density lipoprotein particles in apolipoprotein A-I deficiency. Biochem Biophys Res Commun. 2001 Nov;289(2):395-401. DOI: 10.1006/bbrc.2001.5985

33. Codoner-Franch P, Navarro-Ruiz A, Fernandez-Ferri M, Arilla-Codoner A, Ballester-Asensio E, Valls-Belles V. A matter of fat: insulin resistance and oxidative stress. Pediatr Diabetes. 2012 Aug;13(5):392-9. DOI: 10.1111/j.1399-5448.2011.00847.x

34. Mackness MI, Durrington PN, Mackness B. How high-density lipoprotein protects against the effects of lipid peroxidation. Curr Opin Lipidol. 2000 Aug;11(4):383-8. DOI: 10.1097/00041433-200008000-00007

35. Aviram M, Rosenblat M, Billecke S, Erogul J, Sorenson R, Bisgaier CL, et al. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med. 1999 Apr;26(7-8):892-904. DOI: 10.1016/S0891-5849(98)00272-X

36. Demirel F, Bideci A, Cinaz P, Camurdan MO, Biberoğlu G, Yesilkaya E, et al. Serum leptin, oxidized low density lipoprotein and plasma asymmetric dimethylarginine levels and their relationship with dyslipidaemia in adolescent girls with polycystic ovary syndrome. Clin Endocrinol (Oxf). 2007 Jul;67(1):129-34. DOI: 10.1111/j.1365-2265.2007.02849.x

37. Kelishadi R, Cook SR, Amra B, Adibi A. Factors associated with insulin resistance and nonalcoholic fatty liver disease among youths. Atherosclerosis. 2009 Jun;204(2):538-43. DOI: 10.1016/j.atherosclerosis.2008.09.034

38. Kelly AS, Jacobs DR, Sinaiko AR, Moran A, Steffen LM, Steinberger J. Relation of Circulating Oxidized LDL to Obesity and Insulin Resistance in Children. Pediatr Diabetes. 2010 Dec;11(8):552-5. DOI: 10.1111/j.1399-5448.2009.00640.x

39. Johnston N, Jernberg T, Lagerqvist B, Siegbahn A, Wallentin L. Improved Identification of Patients with Coronary Artery Disease by the Use of New Lipid and Lipoprotein Biomarkers. Am J Cardio. 2006 Mar 1;97(5):640-45. DOI: 10.1016/j.amjcard.2005.09.123

40. Li R, Oteiza A, Sørensen KK, McCourt P, Olsen R, Smedsrød B, et al. Role of liver sinusoidal endothelial cells and stabilins in elimination of oxidized low-density lipoproteins. Am J Physiol Gastrointest. Liver Physiol. 2011 Jan;300(1):G71-81. DOI: 10.1152/ajpgi.00215.2010

Revista Romana de Medicina de Laborator

Romanian Journal of Laboratory Medicine

Journal Information


IMPACT FACTOR 2018: 0,800
5-year IMPACT FACTOR: 0,655



CiteScore 2017: 0.31

SCImago Journal Rank (SJR) 2018: 0.194
Source Normalized Impact per Paper (SNIP) 2018: 0.306

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 258 176 32
PDF Downloads 102 86 18